Moderna (MRNA) is trading sharply lower as investors reprice regulatory risk tied to its investigational seasonal influenza vaccine, mRNA-1010. The stock’s decline reflects lingering uncertainty created by the FDA’s refusal-to-file action earlier in 2026 and the market’s concern that any additional regulatory friction could delay commercialization and downstream combination-vaccine plans.

In February 2026, the FDA issued a refusal-to-file decision on Moderna’s mRNA-1010 application, citing clinical-trial design concerns rather than new safety or efficacy red flags. While the FDA has since agreed to proceed with a review in March 2026, the episode introduced headline risk around what additional analyses the agency may require and whether the process could compress timelines or complicate launch planning.

MRNA’s near-term narrative depends on converting its respiratory pipeline into durable, non-COVID revenue streams. mRNA-1010 is viewed as a cornerstone product because it can serve as a standalone flu franchise and as a platform enabler for next-generation combination shots; any perceived delay can push expected cash-flow inflection further out and amplify sensitivity to guidance, cash burn, and funding expectations.

Traders are likely to focus on any FDA communications that clarify review milestones (including meeting outcomes and potential data requests), plus upcoming 2026 pipeline catalysts and the company’s next earnings update for refreshed commercial and expense outlook. Clearer visibility on U.S. regulatory path for mRNA-1010 could be a key trigger for stabilizing sentiment, while ambiguity could keep volatility elevated.